Disease · MONDO_0006604

rosacea

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. rosacea. Diseases, record MONDO_0006604. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006604

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: rosacea; Open Targets
Open Targets ID: MONDO_0006604; Open Targets
Other names: Acne roscea, Acne, erythematosa, acne rosacea; Open Targets
Disease Ontology: DOID:8881; Disease Ontology
MeSH: D012393; MeSH
NCI Thesaurus: C97136; NCI Thesaurus
Highest stage of its drugs: Approval, for 10 of its 49 drugs, from DailyMed and TTD; Open Targets

Drugs49

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
AZELAIC ACID	CHEMBL1238	Small molecule	Approval	DailyMed	17	13	13	Drugs and targets
DOXYCYCLINE	CHEMBL1200699	Small molecule	Approval	DailyMed	14	11	11	Drugs and targets
METRONIDAZOLE	CHEMBL137	Small molecule	Approval	DailyMed	41	10	10	Drugs and targets
IVERMECTIN	CHEMBL6067487		Approval	DailyMed	10	8	8	Drugs and targets
OXYMETAZOLINE HYDROCHLORIDE	CHEMBL1200791	Small molecule	Approval	DailyMed	4	3	3	Drugs and targets
MINOCYCLINE HYDROCHLORIDE	CHEMBL1200881	Small molecule	Approval	DailyMed	4	2	2	Drugs and targets
BRIMONIDINE TARTRATE	CHEMBL1200389	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets
CLOBETASOL	CHEMBL1201362	Small molecule	Approval	TTD	1	0	0	Drugs and targets
CLOCORTOLONE ACETATE	CHEMBL2106011	Small molecule	Approval	TTD	1	0	0	Drugs and targets
DIFLORASONE DIACETATE	CHEMBL1200545	Small molecule	Approval	TTD	1	0	0	Drugs and targets

1 to 10 of 49

See all 49 drugs

Targets64

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
ADRA2A	Adrenergic receptor alpha	4	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/150	Drugs and targets
ADRA2B	Adrenergic receptor alpha	4	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/151	Drugs and targets
ADRA2C	Adrenergic receptor alpha	4	Adrenergic receptor alpha agonist; Adrenergic receptor alpha-2 agonist	Approval	https://conductscience.org/library/genes/152	Drugs and targets
SNAP25	Synaptosomal-associated protein 25	3	Synaptosomal nerve-associated protein 25 (SNAP-25) hydrolytic enzyme; Synaptosomal nerve-associated protein 25 (SNAP-25) inhibitor	Phase 2	https://conductscience.org/library/genes/6616	Drugs and targets
ADRA1A	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist	Approval	https://conductscience.org/library/genes/148	Drugs and targets
ADRA1B	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist	Approval	https://conductscience.org/library/genes/147	Drugs and targets
ADRA1D	Adrenergic receptor alpha	2	Adrenergic receptor alpha agonist	Approval	https://conductscience.org/library/genes/146	Drugs and targets
KDR	Vascular endothelial growth factor receptor	2	Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor	Phase 2	https://conductscience.org/library/genes/3791	Drugs and targets
MMP1	Interstitial collagenase	2	Matrix metalloproteinase-1 inhibitor	Approval	https://conductscience.org/library/genes/4312	Drugs and targets
MMP13	Collagenase 3	2	Matrix metalloproteinase 13 inhibitor	Approval	https://conductscience.org/library/genes/4322	Drugs and targets

1 to 10 of 64

See all 64 targets

Trials78

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 1 more is not shown, since the checks do not confirm it.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00892281	ORCA - Oracea® for Rosacea: A Community-based Assessment	Phase 4	1,421	2010-11-18	Rosacea	DOXYCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT02120924	A Study to Evaluate the Safety and Clinical Study of Azelaic Acid Gel 15% in Patients With Moderate Facial Rosacea	Phase 3	1,009	2020-06-02	Rosacea	AZELAIC ACID	Its record names the disease	ClinicalTrials.gov
NCT01493947	CD5024 1% [Ivermectin 1%] Cream Versus Metronidazole 0.75% Cream in Papulopustular Rosacea (PPR) Study	Phase 3	962	2015-10-28	Papulopustular Rosacea	IVERMECTIN, METRONIDAZOLE	Open Targets' reading of its record	ClinicalTrials.gov
NCT01555463	Safety and Efficacy of Azelaic Acid Foam, 15 % in Papulopustular Rosacea	Phase 3	961	2015-01-27	Papulopustular Rosacea	AZELAIC ACID, VEHICLE	Open Targets' reading, confirmed by NLM's indexing of its papers	ClinicalTrials.gov
NCT03287791	A Study to Evaluate Safety and Equivalence of Generic Azelaic Acid Foam and Finacea® Foam in Participants With Rosacea	Phase 3	924	2019-07-17	Rosacea	AZELAIC ACID	Its record names the disease	ClinicalTrials.gov
NCT04608500	A Study (Study 2) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea	Phase 3	771	2020-12-16	Facial Papulopustular Rosacea	MINOCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT03142451	A Study (Study 1) to Evaluate the Safety and Efficacy of FMX103 1.5% Topical Minocycline Foam in the Treatment of Facial Papulopustular Rosacea	Phase 3	751	2020-12-17	Facial Papulopustular Rosacea	MINOCYCLINE	Its record names the disease	ClinicalTrials.gov
NCT01494467	Phase 3 Papulopustular Rosacea Study	Phase 3	688	2015-01-16	Papulopustular Rosacea	AZELAIC ACID, IVERMECTIN	Open Targets' reading of its record	ClinicalTrials.gov
NCT02800148	Bioequivalence Study of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea on the Face	Phase 3	667	2020-12-09	Rosacea	AZELAIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02795117	Comparative Safety and Efficacy of Two Treatments in the Treatment of Inflammatory Lesions of Rosacea	Phase 3	486	2021-01-05	Rosacea	IVERMECTIN	Its record names the disease	ClinicalTrials.gov

1 to 10 of 78

See all 78 trials

Comparisons in its trials34

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Oracea® as Monotherapy vs Oracea® as add-on Therapy: Number of Treatment Responders at Endpoint, Where Response is Defined as an IGA Score of 0 (Clear) or 1 (Near Clear)	616 of 1,197	106 of 224	1,421	NCT00892281	Trial comparisons
Oracea® as Monotherapy vs Oracea® as add-on Therapy: serious adverse events	5 of 1,196	0 of 224	1,420	NCT00892281	Trial comparisons
Azelaic Acid Foam, 15% (BAY39-6251) vs Vehicle Foam: serious adverse events	3 of 483	4 of 478	961	NCT01555463	Trial comparisons
FMX103 1.5% vs Vehicle Foam: deaths from any cause	0 of 514	0 of 257	771	NCT04608500	Trial comparisons
FMX103 1.5% vs Vehicle Foam: serious adverse events	1 of 514	2 of 257	771	NCT04608500	Trial comparisons
FMX103 1.5% vs Vehicle Foam: deaths from any cause	0 of 494	1 of 256	750	NCT03142451	Trial comparisons
FMX103 1.5% vs Vehicle Foam: serious adverse events	2 of 494	3 of 256	750	NCT03142451	Trial comparisons
Azelaic Acid Foam, 15% (BAY39-6251) vs Vehicle Foam: serious adverse events	1 of 198	3 of 203	401	NCT01025635	Trial comparisons
Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules vs Ivermectin 1% Cream + Oral Placebo Capsules: deaths from any cause	0 of 135	0 of 138	273	NCT03075891	Trial comparisons
Ivermectin 1% Cream + Doxycycline 40 mg MR Capsules vs Ivermectin 1% Cream + Oral Placebo Capsules: serious adverse events	1 of 135	1 of 138	273	NCT03075891	Trial comparisons

1 to 10 of 34

See all 34 comparisons in its trials

Papers from its trials21

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
39710117	RESULT	1	PubMed
39681269	RESULT	1	PubMed
39136023	RESULT	1	PubMed
35929658	RESULT	1	PubMed
35385049	RESULT	1	PubMed
34840653	RESULT	1	PubMed
34233378	RESULT	1	PubMed
33548303	RESULT	1	PubMed
32989925	RESULT	1	PubMed
32360760	RESULT	1	PubMed

1 to 10 of 21

See all 21 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0006604

GET https://conductscience.org/api/diseases/v1/MONDO_0006604/drugs?page=2

API reference For AI assistants